This isn't a particularly healthy environment for smaller med-techs, and Wright Medical Group (NASDAQ:WMGI) is paying the price for that sector weakness. There wasn't anything particularly wrong with Wright Medical's second quarter report, and the company continues to perform exceptionally well in the fast-growing extremities market, but there was nothing new to push analysts or investors to a more positive outlook. With market share growth potential in lower extremities, an upcoming FDA decision on Augment, and the balance sheet flexibility to do deals, there are still good reasons to hold Wright Medical, but the discount to fair value doesn't scream "must buy" right now.
Getting The Job Done, Though Only Just
Wright Medical was basically on target, but...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|